Lok Sabha Question No. 389 (STARRED), answered on 2019-07-19
Subject: Anti-Diabetics Ayurvedic Drug
Ministry: AYURVEDA,YOGA & NATUROPATHY,UNANI,SIDDHA AND HOMEOPATHY (AYUSH)
Asked by: Feroze Varun Gandhi

## GOVERNMENT OF INDIA MINISTRY OF AYURVEDA, YOGA & NATUROPATHY, UNANI, SIDDHA AND HOMOEOPATHY (AYUSH)

## LOK SABHA STARRED QUESTION NO. 389 TO BE ANSWERED ON 19 TH JULY, 2019

## ANTI - DIABETICS AYURVEDIC DRUG

## *389. SHRI FEROZE VARUN GANDHI:

Will  the  Minister  of  AYURVEDA,  YOGA  AND  NATUROPATHY, UNANI, SIDDHA AND HOMOEOPATHY (AYUSH) be pleased to state:

- (a) whether the anti - diabetics Ayurvedic drug BGR - 32 is ready for use after al the standardized and scientific clinical tests, if so, the det ails thereof;
- (b)  whether  the  Government  has  any  plans  to  make  it  available  in Government hospitals and dispensaries in the country;
- (c) if so, the details thereof along with infrastructural mechanism av present planning for its uses by the patients; and
- (d) the details of the steps taken for induction of doctors from alter medicine stream into primary healthcare centres in the country?

## ANSWER THE MINISTER OF STATE(IC) OF THE MINISTRY OF AYURVEDA, YOGA & NATUROPATHY, UNANI, SIDDHA AND HOMOEOPATHY (SHRI SHRIPAD YESSO NAIK)

(a) to (d ):A statement is laid on the Table of the House

## STATEMENT REFERRED TO IN REPLY TO LOK SABHA STARRED QUESTION NO. 389 FOR 19 TH JULY, 2019

(a) to (c )BGR - 32 is not known so far to the Government as an Ayurvedic d developed, manufactured and marketed for anti - diabetic use. However, Council of  Scientific  and  Industrial  Research  (CSIR)  constituent  laboratorie CSIR - Central  Institute  of  Medicinal  &  Aromatic  Plants  (CSIR - CIMAP), Lucknow; and CSIR - National Botanical Research Institute (CSIR - NBRI), Lucknow have jointly developed a scientifically studied herbal produ NBRMAP - DB  as  hypoglycemic formulation. The knowhow and technology of the  product  was  transferred  to  M/s  AIMIL  Pharma  Limited,  Delhi  and obtained license for manufacturing and marketing the formulation as Ayu c product under the branded name 'BGR -34' with claim of positive effects against Type-II Diabetes for having shown improvement in normalizing blood glu level along with better quality of life. BGR - 34 is known for its availability in market in vario us parts of the country and also through online shopping Being a branded or proprietary Ayurvedic product, BGR - 34 does not qualify for inclusion in the Essential Drug List published by the Ministry of AYUSH for facilitating supply of medicine s to dispensaries & hospitals in the states National AYUSH Mission.  Nevertheless, it is the prerogative of the Gove procurement agencies to consider making formulary or list of medicine procured for hospitals and dispensaries following the stipulated codal formalitie and  procedures.  Also,  the  prerogative  is  vested  with  the  doctors  t prescribing  BGR - 34 or  not in accordance with  their confidence in effectiveness of the product as well as the disease condition of individ betic patients.

(d)  Mainstreaming of AYUSH is one of the strategies outlined in the N Health Policy - 2017 and National Health Mission under which AYUSH facilitie are  created  and  co - located  in  healthcare  delivery  network.  In  this  dire grant - in - aid is provided to the States and 15172 AYUSH facilities have be -located  in  the  Primary  Health  Centres,  Community  Health  Centres,  Di Hospitals  etc.  and  11837  AYUSH  medical  officers  inducted.  7622  Prim Health Centres in the country are repo rted to have included AYUSH services and AYUSH practitioners. The engagement of AYUSH doctors and paramedics in the Primary Health Centres and their training is supported by the Ministr Health  &  Family  Welfare  under  National  Health  Mission  (NHM),  while the support  for  AYUSH  infrastructure,  equipment,  furniture  and  medicine provided by the Ministry of AYUSH under National AYUSH Mission (NAM).

- *****